Clinical Trial: A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07833098) titled 'A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension' on Sept. 01.

Brief Summary: A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Hypertension Resistant Hypertension Uncontrolled Hypertension

Intervention: DRUG: VB19055 Dose A QD

VB19055 Dose A orally once daily (QD) for 12 weeks

DRUG: VB19055 Dose B QD

VB19055 DoseB orally once daily (QD) for 12 weeks

DRUG: VB19055 Dose C QD

VB19055 Dose C ora...